Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on Montelukast for COVID-19 Patients at Higher Risk of Complications in the Community

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for COVID-19 in patients who are at a higher risk of experiencing severe illness. The trial will explore the effectiveness of different treatments provided in primary care settings. One of the treatments being studied is a medication called Montelukast, which is taken as a film-coated tablet. This medication is commonly used to manage asthma and allergies by reducing inflammation in the airways.

The purpose of the study is to determine how well these treatments help patients recover from COVID-19. Participants in the study will be randomly assigned to receive either the treatment or usual care, which may include a placebo. The study will track the time it takes for participants to feel fully recovered from their symptoms, as well as other health outcomes such as hospital visits and overall well-being.

Throughout the study, participants will be asked to keep a daily diary to record their recovery progress. This will help researchers understand how the treatments impact recovery time and overall health. The trial aims to create a framework for future studies in primary care settings, not only for COVID-19 but also for other emerging diseases.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be asked to provide informed consent. This means you agree to participate and understand the procedures involved.

    You will need to confirm a positive test for SARS-CoV-2 infection, which is the virus that causes COVID-19. This test should have been taken fewer than 15 days ago, and you should be experiencing symptoms of COVID-19.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to ensure you meet the criteria for the study. This includes being between 18-64 years old with certain health conditions or being 65 years or older.

    Your symptoms and medical history will be reviewed to determine your eligibility.

  3. Step 3

    Treatment phase

    If eligible, you will receive a treatment, which may include montelukast. This is a film-coated tablet taken orally.

    The dosage is 10 mg, and it is taken once daily. The duration of administration will be specified by the study team.

  4. Step 4

    Daily diary

    You will be asked to keep a daily diary to record your recovery progress. Each day, you will answer the question: 'Do you feel fully recovered today?' with a yes or no.

    This diary helps track your recovery over a period of 28 days from the start of the treatment.

  5. Step 5

    Follow-up and monitoring

    Throughout the study, your health will be monitored. This includes checking for any hospital admissions, oxygen administration, or other medical interventions.

    Your overall well-being will be assessed using the WHO Well-being Index and other measures.

  6. Step 6

    Completion of the study

    At the end of the study period, your participation will conclude. You will have a final assessment to review your health status and any outcomes related to the study.

    The study aims to understand the effectiveness of treatments in reducing the time to recovery from COVID-19.

Who can join the trial?

14 criteria

  • The participant must be willing and able to give informed consent to join the study. This means they understand the study and agree to take part.
  • The participant must be willing to follow all the procedures of the trial.
  • The participant must have a positive test for SARS-CoV-2 infection (this is the virus that causes COVID-19). The test can be PCR, LAMP, antigen, or a self-test.
  • The positive test must have been taken fewer than 15 days ago.
  • The participant must be feeling unwell with symptoms of COVID-19, such as shortness of breath, general feeling of being unwell, muscle pain, diarrhea, vomiting, fever, or cough. These symptoms must have started fewer than 15 days ago.
  • Participants aged 18-64 years must have one of the following conditions that make them more vulnerable:
    • Severe chronic problems with the airways and lungs, requiring treatment by a lung specialist.
    • Chronic heart problems that make the participant eligible for the flu vaccine.
    • Diabetes mellitus that is poorly controlled or has other related health issues.
    • Severe kidney problems requiring dialysis or a kidney transplant.
    • Reduced ability to fight infections due to autoimmune diseases, organ or stem cell transplants, blood diseases, lack of a spleen, severe immune disorders, or recent chemotherapy.
    • Untreated HIV infection or an HIV infection with a CD4 count higher than 200.
    • Severe liver disease classified as Child-Pugh B or C.
    • Morbid obesity (a body mass index, BMI, greater than 40).
    • Participants aged 65 years or older can join the study without needing to have any of the above conditions.

Who cannot join the trial?

6 criteria

  • Patients who do not have **COVID-19**.
  • Patients who are not referred by their **general practitioner** (family doctor).
  • Patients who are not at a higher risk of a **complicated illness course** (meaning their illness is not expected to become severe).
  • Patients who are not part of the age groups specified for the study.
  • Patients who are not male or female, as both genders are included in the study.
  • Patients who are considered part of a **vulnerable population** (groups that may need special protection or care).
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

PLATFORM-COVID study is a clinical trial that aims to evaluate the effectiveness of different treatments for COVID-19 in patients who are at higher risk of severe illness. The trial is conducted in general practice settings, meaning it takes place in local healthcare facilities rather than hospitals. The goal is to find out which treatments help patients recover faster from COVID-19. The study also aims to create a system that can be used for future research on COVID-19 and other new diseases in the community. Unfortunately, the specific medications or therapies being tested in this trial are not listed in the provided data. If you have more information or specific names of the treatments being studied, I can help describe them further.

What is already known about the treatment

COVID-19 Treatment – This medication is administered to patients with COVID-19 who are at higher risk of severe illness, as referred by their general practitioner. It is currently being studied in a clinical trial to evaluate its effectiveness in helping patients recover more quickly from COVID-19 when treated in a primary care setting. The main therapeutic goal is to reduce the time to recovery for these patients. The medication works by targeting specific pathways in the body that the virus uses to replicate, thereby slowing down the progression of the disease. It is classified as an antiviral agent, which means it is designed to combat viral infections.

Investigated diseases

COVID-19 – COVID-19 is a respiratory illness caused by the coronavirus SARS-CoV-2. It primarily spreads through respiratory droplets when an infected person coughs, sneezes, or talks. The disease can start with mild symptoms such as fever, cough, and fatigue, but it may progress to more severe conditions like difficulty breathing and pneumonia. In some cases, it can lead to complications affecting other organs, including the heart and kidneys. The progression of symptoms can vary widely among individuals, with some experiencing mild illness and others developing severe symptoms. Recovery times also differ, with some people recovering quickly and others experiencing prolonged symptoms.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-500678-33-00Protocol codeNL79504.068.21Estimated enrolment1 200 patientsSponsorUniversiteit Maastricht

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).